Pharminent

Sitagliptin is ‘Safest’ DPP-4 Inhibitor for Type 2 Diabetes

Detailed assessment of heart-failure outcomes from TECOS study with the type 2 diabetes drug sitagliptin is published and confirms that this DPP-4 inhibitor has the safest cardiovascular profile. Medscape Medical News http://www.medscape.com/viewarticle/861939

Filed under: Diabetes, DPP-4

Januvia and Janumet: Merck’s Blockbuster Diabetes Products

http://finance.yahoo.com/news/januvia-janumet-merck-blockbuster-diabetes-130737473.html

Filed under: Diabetes, DPP-4

Merck says expects januvia to retain strong position as addon diabetes therapy despite favorable data seen with lilly’s rival jardiance

Says januvia sales got a $100 million boost in third quarter from timing of customer buying http://www.bioportfolio.com/news/article/2504497/BRIEF-Merck-says-expects-januvia-to-retain-strong-position-as-add-on.html

Filed under: Diabetes, DPP-4

DPP4 inhibitors show benefits over sulfonylureas as addon diabetes therapy

Patients with diabetes who add dipeptidyl peptidase4 inhibitors to their metformin therapy have a lower risk of stroke and hypoglycaemia study shows. http://www.bioportfolio.com/news/article/2493627/DPP-4-inhibitors-show-benefits-over-sulfonylureas-as-add-on-diabetes-therapy.html

Filed under: Diabetes, DPP-4

Add-on sitagliptin cuts risk of insulin initiation in T2DM

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM) treated with metformin, add-on sitagliptin is associated with a lower risk of insulin initiation than add-on sulphonylurea, according to a study published in the October issue of Diabetes, Obesity and Metabolism. http://medicalxpress.com/news/2015-10-add-on-sitagliptin-insulin-t2dm.html

Filed under: Diabetes, DPP-4

Japan First To Approve Omarigliptin, Lusutrombopag

The latest batch of product approvals in Japan includes the first regulatory clearances worldwide for new molecules from Merck and Shionogi, in a further sign that the country’s “drug lag” is a thing of the past. https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/9/30/Japan-First-To-Approve-Omarigliptin-Lusutrombopag

Filed under: Diabetes, DPP-4

Merck’s once-weekly diabetes drug approved in Japan

Reuters The drug, omarigliptin, belongs to the same class of drugs as Merck’s bestseller Januvia, which is to be taken once a day. Both drugs are aimed at lowering blood sugar levels. Januvia had sales of about $4 billion in 2014. Merck said this month it would … http://www.reuters.com/article/2015/09/28/merck-co-diabetesdrug-idUSL3N11Y3M220150928

Filed under: Diabetes, DPP-4

Onglyza and Kombiglyze XR Excluded from Express Scripts 2016 Formulary Due to Safety Concerns

That means that patients using this drug may have to pay the full retail price for it. Why would the company refuse to help patients afford Onglyza? It has to do with recent warnings concerning potentially serious side effects associated with the drug. http://newyork.legalexaminer.com/fda-prescription-drugs/onglyza-and-kombiglyze-xr-excluded-from-express-scripts-2016-formulary-due-to-safety-concerns/

Filed under: Diabetes, DPP-4

How Eli Lilly and Co (LLY) Jardiance Can Crash Merck & Co. Januvia Franchise

Eli Lilly and Co. (NYSE:LLY) released stellar results from a long-term study testing its type 2 diabetes drug, Jardiance, last week. The drug showed significant success in lowering the risk of cardiovascular incidents including heart attacks, strokes … http://www.bidnessetc.com/53467-how-eli-lilly-and-co-lly-jardiance-can-crash-merck-co-januvia-franchise/

Filed under: Diabetes, DPP-4

Categories